Deep Track Capital, LP
About Deep Track Capital, LP’s 13F portfolio
Deep Track Capital, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Deep Track Capital, LP reported $6.8B across 66 US-listed positions (). Its largest position is GUARDANT HEALTH INC (GH) at 7.5% of the reported book, and its ten biggest holdings make up 40% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: GH GUARDANT HEALTH INC | $145.14 +1.30% | 7.5% | 3.4M | $509.1M |
| 2 | NASDAQ: IMVT IMMUNOVANT INC | $33.17 −0.12% | 5.3% | 9.3M | $359.9M |
| 3 | NASDAQ: GPCR STRUCTURE THERAPEUTICS INC | $17.36 −4.46% | 3.7% | 4.7M | $254.4M |
| 4 | NASDAQ: PCVX VAXCYTE INC | $58.52 −1.48% | 3.7% | 4.3M | $250.0M |
| 5 | NASDAQ: ALNY ALNYLAM PHARMACEUTICALS INC | $149.40 −4.54% | 3.7% | 825K | $248.3M |
| 6 | NYSE: MANE VERADERMICS INC | — — | 3.6% | 2.0M | $245.9M |
| 7 | NASDAQ: TARS TARSUS PHARMACEUTICALS INC | $75.95 −2.88% | 3.4% | 3.7M | $230.8M |
| 8 | NASDAQ: NUVL NUVALENT INC | $123.96 0.00% | 3.2% | 1.8M | $220.2M |
| 9 | NASDAQ: ALKS ALKERMES PLC | $46.85 +3.08% | 3.1% | 4.0M | $209.6M |
| 10 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | $5.94 −1.33% | 2.8% | 19.7M | $193.3M |
| 11 | NASDAQ: BMRN BIOMARIN PHARMACEUTICAL INC | $61.43 +4.99% | 2.8% | 3.3M | $189.3M |
| 12 | NASDAQ: NRIX NURIX THERAPEUTICS INC | $14.10 −0.98% | 2.8% | 7.7M | $187.7M |
| 13 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | $95.74 −0.60% | 2.7% | 1.9M | $183.3M |
| 14 | NASDAQ: ALMS ALUMIS INC | $4.40 −9.19% | 2.6% | 6.3M | $178.6M |
| 15 | NASDAQ: IONS IONIS PHARMACEUTICALS INC | $27.39 +1.59% | 2.6% | 2.2M | $174.4M |
| 16 | NASDAQ: CMPS COMPASS PATHWAYS PLC | $8.12 +1.75% | 2.5% | 12.2M | $172.1M |
| 17 | NASDAQ: VERA VERA THERAPEUTICS INC | $25.58 −2.37% | 2.5% | 4.0M | $171.6M |
| 18 | NASDAQ: AXSM AXSOME THERAPEUTICS INC. | $134.00 −1.43% | 2.5% | 700K | $171.3M |
| 19 | NASDAQ: GMAB GENMAB A/S | $50.97 −1.91% | 2.3% | 5.7M | $155.2M |
| 20 | NASDAQ: MLTX MOONLAKE IMMUNOTHERAPEUTICS | $10.79 −4.09% | 2.0% | 7.0M | $136.3M |
| 21 | NASDAQ: COAG HEMAB THERAPEUTICS HLDGS INC | — — | 1.9% | 3.6M | $132.3M |
| 22 | NASDAQ: TNGX TANGO THERAPEUTICS INC | $21.89 −1.00% | 1.9% | 4.2M | $131.3M |
| 23 | NASDAQ: DFTX DEFINIUM THERAPEUTICS INC | — — | 1.9% | 2.8M | $129.4M |
| 24 | NASDAQ: GRAL GRAIL INC | $102.10 −3.57% | 1.8% | 1.8M | $125.3M |
| 25 | NASDAQ: BCAX BICARA THERAPEUTICS INC | $9.38 −2.29% | 1.8% | 4.1M | $121.7M |
Showing 1–25 of 66 positions on this page reported in this 13F.
- Healthcare92%
- AddedGHGUARDANT HEALTH INC+1.6%$509.1M
- AddedGPCRSTRUCTURE THERAPEUTICS INC+10.8%$254.4M
- NewALNYALNYLAM PHARMACEUTICALS INC—$248.3M
- AddedMANEVERADERMICS INC+300%$245.9M
- AddedTARSTARSUS PHARMACEUTICALS INC+1.9%$230.8M
- AddedNUVLNUVALENT INC+29.6%$220.2M
- AddedALKSALKERMES PLC+11.4%$209.6M
- AddedBMRNBIOMARIN PHARMACEUTICAL INC+188%$189.3M
- AddedNRIXNURIX THERAPEUTICS INC+21.9%$187.7M
- AddedIONSIONIS PHARMACEUTICALS INC+12.8%$174.4M
- ReducedIMVTIMMUNOVANT INC−19.0%$359.9M
- ReducedORKAORUKA THERAPEUTICS INC−5.3%$183.3M
- ReducedALMSALUMIS INC−6.3%$178.6M
- ReducedVERAVERA THERAPEUTICS INC−2.6%$171.6M
- ReducedAXSMAXSOME THERAPEUTICS INC.−36.4%$171.3M
- ReducedDFTXDEFINIUM THERAPEUTICS INC−8.3%$129.4M
- ReducedMBXMBX BIOSCIENCES INC−37.2%$95.6M
- ReducedCYTKCYTOKINETICS INC−49.1%$59.6M
- ReducedDYNDYNE THERAPEUTICS INC−25.0%$33.3M
- ReducedXFORX4 PHARMACEUTICALS INC−7.3%$27.5M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | TCXB TCGX Acquisition Corp. II | 13G | 9.9% | 990K | Filed 23 OCT 2026 |
| 2 | FLSC Frazier Life Sciences Acquisition Corp. II | 13G | 9.0% | 700K | Filed 21 OCT 2026 |
| 3 | COAG Hemab Therapeutics Holdings, Inc. | 13G | 8.2% | 3.6M | Filed 08 MAY 2026 |
| 4 | ATTO Attovia Therapeutics, Inc. | 13G | 7.5% | 3.2M | Filed 12 AUG 2026 |
| 5 | GPCR Structure Therapeutics Inc. | 13G | 7.2% · 2 classes | 15.0M | Filed 16 NOV 2026 |
| 6 | LTGO Latigo Biotherapeutics, Inc. | 13G | 7.0% | 4.4M | Filed 13 AUG 2026 |
| 7 | ENGN enGene Holdings Inc. | 13G | 6.7% | 4.3M | Filed 18 NOV 2025 |
| 8 | BCAX Bicara Therapeutics Inc. | 13G | 6.2% · 2 classes | 4.1M | Filed 15 MAY 2026 |
| 9 | JTTT JATT III Acquisition Corp | 13G | 5.8% | 450K | Filed 02 SEP 2026 |
| 10 | GERN Geron Corp | 13G | 5.1% | 32.5M | Filed 13 FEB 2026 |
Showing all 10 disclosed stakes.
Reading Deep Track Capital, LP’s 13F portfolio
Deep Track Capital, LP’s $6.8B 13F book is spread across 66 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 40%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are GH, IMVT, GPCR, PCVX and ALNY, led by GUARDANT HEALTH INC (GH) at 7.5% of the portfolio. The heaviest sector exposure is Healthcare (92%).
What Deep Track Capital, LP changed last quarter
Between 2026-03-31 and Q2 2026, Deep Track Capital, LP was a net buyer: it opened 18 new positions and added to 22 more, while trimming 15 and closing 14 outright. Against a 66-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was GUARDANT HEALTH INC (GH), and its biggest reduction was IMMUNOVANT INC (IMVT).
What a 13F does and doesn’t reveal
A 13F captures only Deep Track Capital, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Deep Track Capital, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Deep Track Capital, LP's profile on this page is built directly from those filings.
How current is the 13F data on Deep Track Capital, LP's page?
It reflects Deep Track Capital, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Deep Track Capital, LP files its next quarterly report, this page refreshes automatically.
Can I see Deep Track Capital, LP's complete list of holdings?
This page highlights Deep Track Capital, LP's largest positions rather than all 66 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Deep Track Capital, LP's filings.
Does a 13F show everything Deep Track Capital, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Deep Track Capital, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Deep Track Capital, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

